One-pot synthesis of orthogonally protected dipeptide selenazoles employing NÎ±-amino selenocarboxamides and Î±-bromomethyl ketones by Madhu, C. et al.
Tetrahedron Letters 55 (2014) 6831–6835Contents lists available at ScienceDirect
Tetrahedron Letters
journal homepage: www.elsevier .com/ locate/ tet le tOne-pot synthesis of orthogonally protected dipeptide
selenazoles employing Na-amino selenocarboxamides
and a-bromomethyl ketoneshttp://dx.doi.org/10.1016/j.tetlet.2014.10.085
0040-4039/ 2014 Elsevier Ltd. All rights reserved.
⇑ Corresponding author. Tel.: +91 80 22961339/8147757961.
E-mail addresses: narendrachem@gmail.com (N. Narendra), sureshbabuvommi-
na@rediffmail.com, hariccb@hotmail.com, hariccb@gmail.com (V.V. Sureshbabu).Chilakapati Madhu a, Nageswara Rao Panguluri a, N. Narendra b, V. Panduranga a,
Vommina V. Sureshbabu a,⇑
a#109, Peptide Research Laboratory, Department of Studies in Chemistry, Central College Campus, Bangalore University, Dr. B.R. Ambedkar Veedhi, Bangalore 560 001, India
bDepartment of Chemistry, Government Science College, Tumkur University, B.H. Road, Tumkur 572 103, India
a r t i c l e i n f o a b s t r a c tArticle history:
Received 30 May 2014
Revised 13 October 2014
Accepted 14 October 2014
Available online 22 October 2014
Keywords:
Amino nitrile
Phosphorus pentaselenide
Na-Amino selenocarboxamide
a-Bromomethyl ketone
SelenazoleA simple and efﬁcient protocol for the synthesis of selenazole containing dipeptidomimetics using
Na-amino selenocarboxamides and a-bromomethyl ketones is described. All the compounds made were
isolated in good yields and fully characterized.
 2014 Elsevier Ltd. All rights reserved.Selenium is an essential trace element for higher organisms and
the enzymes which contain selenium such as glutathione peroxi-
dase (GPX), 5-deiodase type-1 play an important role in human
physiology.1 In recent years organoselenium derivatives have
shown marked biological and enzyme inhibitory activities.2,3
Notably, selenazole derivatives are one of the signiﬁcant groups
of organoselenium compounds due to their pharmacological rele-
vance and are of interest in the ﬁeld of material science.4 Molecules
containing this functional group possess strong inhibitory activity
against inducible nitric oxide synthase.5 The prominent examples
are selenazofurin, a potent known antiviral agent, 2-piperidinosel-
enazole and 4-phenyl-2-piperidinoselenazole, which exhibit
superoxide anion-scavenging activity.6
Selenocarboxamides are a class of reactive intermediates,
similar to their oxygen and sulfur analogs. They are important
precursors for the synthesis of biologically active heterocycles like
1,3-selenazoles7 and 1,3-selenazines.8 The reported methods for
the synthesis of selenocarboxamides include the reaction of nitrile
with hydrogen selenide9 (H2Se), sodium hydrogen selenide10
(NaSeH), monoselenophosphate11a, and bis(trimethylsilyl)sele-nide.11b Geisler et al., reported an efﬁcient protocol for the
synthesis of selenocarboxamides from the corresponding nitriles
using phosphorous pentaselenide12 (P2Se5). P2Se5 is a more reliable
reagent because of its ease of preparation, less toxic than NaSeH
or H2Se, and moreover the ability of P2Se5 circumvents the addition
of NEt3/pyridine10 and borontriﬂuoride diethyletherate.11b This
prompted us to opt for P2Se5 toward the synthesis of selenocarbox-
amides from the corresponding Na-protected amino nitriles (Fig. 1).
Recently our group has reported the synthesis of selenoxopep-
tides,13 Nb-protected amino alkyl isoselenocyanate,14 selenourea,15
selenohydantoin,16 selenocarbamate, and selenazole containing
peptidomimetics.17 The utility of both carboxamides, as well as
thiocarboxamide derived from Na-protected amino acids18 as
building blocks for the construction of oxazole/thiazole peptidom-
imetics has been well documented.19 In continuation of our inter-
est on organoselenium compounds, herein we report the one-pot
synthesis of orthogonally protected selenazole dipeptidomimetics
employing Na-Fmoc/Boc/Z protected amino selenocarboxamides
and a-bromomethyl ketone which involves the following retro-
synthetic pathway (Fig. 2).
Initially, the preparation of Na-protected amino nitrile was
undertaken. Na-Protected amino acid was converted to the corre-
sponding carboxamide via its mixed anhydride and then treated
with aqueous ammonia. The resulting amide was subjected with
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Figure 2. Retro-synthetic analysis of orthogonally protected selenazole dipeptidomimetics.
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Figure 1. Structure of P2Se5.
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obtain the nitrile (Scheme 1). Later, elemental Se was heated with
red phosphorus under electric Bunsen burner till the mixture
became glassy black purple solid indicating the formation of
P2Se5. Then it was cooled to rt and powdered thoroughly.
In the next step, the synthesis of Na-protected amino seleno-
carboxamide 2 was carried out (Scheme 1). In a typical procedure
Fmoc-Lue-w[CN] (1.0 equiv) 1b was dissolved in EtOH and freshly
prepared P2Se5 (2.0 equiv) was added. The reaction mixture was
heated to reﬂux and then a few drops of water were added to gen-
erate H2Se, which reacts with nitrile 1b for the formation of the
corresponding selenocarboxamide 2b. After completion of the
reaction, the reaction mixture was ﬁltered and washed with EtOH
to obtain Fmoc-Leu-w[C(@Se)NH2] 2b. The crude residue was puri-
ﬁed by column chromatography and the isolated pure compound
2b was characterized by Mass, 1H, 13C and 77Se NMR spectroscopy.
The 77Se NMR shows a characteristic single peak at around d 529.9
for the selenocarbonyl group. The adoptability and efﬁcacy of the
protocol were further demonstrated by synthesizing a series of
Na-Fmoc/Boc/Cbz selenocarboxamides 2 from the corresponding
nitriles 1 (Table 1).
Heterocyclic amino acids such as oxazoles and thiazoles are sub-
structures comprising numerous macrolactam natural products
having biological activities including cytotoxicity, p-glycoprotein
pump inhibition, and metal binding properties.20 Oxazole contain-
ing amino acids are suitable building blocks for the preparation ofPGHN
R1
OH
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Scheme 1. Synthesis of Na-protectmodel systems with well deﬁned secondary structures. Peptides
containing thiazole subunits are characterized by reduction of
multi drug resistance of certain types of lymphoblasts, antifungal,
antibacterial, antimicrobial, and antitubercular activities.21 The
structure of fascinating selenazole resembleswith oxazole/thiazole.
Different protocols have been reported for the synthesis of selenaz-
oles by using selenoamide22 or selenourea23 as the starting mate-
rial. Selenoureas are inconvenient due to their high cost and low
stability to air and light. In particular Zhang et al., have synthesized
selenazole containing cyclic peptides (QZ59Se-SSS and QZ59Se-
RRR) for crystallization with p-glycoprotein (pgp) but this protocol
is limited to the preparation of Boc-amino selenocarboxamides.24
Thus, the limited applicability with the available literature
prompted us to prepare orthogonally protected dipeptide selenaz-
oles from the corresponding Na-amino selenocarboxamides.
In the next part of our study, the synthesis of Na-urethane
orthogonally protected selenazole linked dipeptidomimetics
was carried out (Scheme 2). In a typical procedure, Fmoc-Leu-
w[C(@Se)NH2] (2b) was reﬂuxed with Boc-Phe-w[C(@O)CH2Br]25
(3b) in acetone to obtain selenazole linked dipeptidomimetic 4b.
The reaction was found to be complete within 30 min, as observed
by TLC analysis. It was also evident by the disappearance of bromo-
methyl ketone peak at around 1735 cm1 in the IR spectrum. The
isolated crude selenazole dipeptidomimetic 4b was puriﬁed
through column chromatography (hexane/EtOAc 9:1%) and
characterized by NMR and mass spectrometry. The generality ofNH2
O
PGHN CN
R1
TFAA, Pyridine
THF,0 °C
PGHN
R1
NH2
Se
2
2O
ed amino selenocarboxamides.
Table 1
List of Na-protected amino selenocarboxamides 2
Entry Nitrile 1 Selenocarboxamide 2 Yield (%) HRMS Obsd. (Calcd)*
a
FmocHN CN FmocHN
NH2
Se
88 473.0744 (473.0735)
b
FmocHN CN FmocHN
NH2
Se
82 439.0901 (439.1012)
c
FmocHN CN
BzlOOC
FmocHN
NH2
Se
BzlOOC
78 531.0799 (531.0682)
d BocHN CN BocHN
NH2
Se
68 275.0275 (275.0315)
e
BocHN CN BocHN
NH2
Se
79 303.0588 (303.0617)
f BocHN CN
NHCbz
BocHN
NH2
Se
NHCbz
64 466.1221 (466.0982)
g CbzHN CN CbzHN
NH2
Se
78 309.0118 (309.0109)
h
CbzHN CN CbzHN
NH2
Se
88 294.9962 (294.1084)
i
CbzHN CN
BzlS
CbzHN
NH2
Se
BzlS
73 431.0308 (431.0314)
j CbzN CN CbzN
NH2
Se
69 335.0275 (335.0186)
* [M+Na]+.
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Scheme 2. Synthesis of orthogonally protected dipeptide selenazoles.
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orthogonally protected dipeptide selenazoles (Table 2).
Using chiral HPLC, the racemization study of the prepared dia-
stereomeric dipeptide selenazoles 4d and 4d⁄ were analyzed. They
showed peaks at Rt = 13.53 min (4d) and Rt = 18.42 min (4d⁄),
respectively. Also intentionally prepared equimolar mixture of 4d
and 4d⁄ showed distinct peaks at Rt = 13.62 and Rt = 18.60 min.These observations inferred that the present protocol was free
from racemization.
In conclusion we have developed a simple protocol for the syn-
thesis of selenazole linked N-orthogonally protected dipeptidomi-
metics by the condensation of Na-amino selenocarboxamides
with a-bromomethyl ketones. Various Na-protected selenocarbox-
amides have also been synthesized.
Table 2
List of orthogonally protected selenazole dipeptidomimetics prepared
4a, yield 82% 4b, yield 78% 4c, yield 81%
4d, yield 75% 4e, yield 79% 4f, yield 83%
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26. (a) General procedure for the preparation of P2Se5
Red phosphorus was washed with anhydrous ether (10 mL) then dried. It
(10 mmol) was taken into glass vial and greyish elemental selenium powder
(25 mmol) was added. The resulting mixture was heated under electric
Bunsen until it turned to glassy black-purple solid and then cooled to rt and
grained.
(b) General procedure for the synthesis of Na-protected amino selenocarboxamides
2a–j.
To a solution of Na-protected amino nitrile (10 mmol) in EtOH (10 mL),
freshly prepared glassy black powdered P2Se5 (20 mmol) was added. The
reaction mixture was reﬂuxed followed by the addition of a few drops of
water. After complete consumption of the starting material (TLC analysis; 3–
4 h), the reaction mixture was ﬁltered. The solvent was removed in vacuo and
the crude residue was puriﬁed by column chromatography (hexane/EtOAc
8:2%).
(c) General procedure for the synthesis of orthogonally protected dipeptide
selenazoles 4a–f
To a solution of Na-protected amino selenocarboxamide (10 mmol) in dry
acetone (10 mL), Na-protected amino acid derived bromomethylketone
(10 mmol) was added. The reaction mixture was reﬂuxed for about 30 min.
After completion of the reaction, the solvent was removed in vacuo and the
crude residue was puriﬁed by column chromatography (hexane/EtOAc 9:1%)
to obtain the pure dipeptide selenazole in good yield.
27. Characterization data for selected compounds
Compound 2a: 1H NMR (300 MHz, DMSO-d6): d 2.91 (d, 2H, J = 6.8 Hz), 3.94 (t,
1H, J = 5.4 Hz), 4.36 (t, 1H, J = 4.8 Hz), 4.59 (d, 2H, J = 4.8 Hz), 6.12 (br, 1H),
7.12–7.55 (m, 13H), 9.83 (br s, 1H), 10.26 (br s, 1H); 13C NMR (75 MHz, DMSO-
d6): d 40.1, 48.3, 51.7, 66.9, 122.6, 125.2, 126.2, 127.7, 128.0, 128.3, 128.7,
139.3, 141.0, 143.5, 152.4, 196.1; 77Se NMR (75 MHz, DMSO-d6): d 490.5;
HRMS (m/z) calcd for: C24H22N2O2SeNa 473.0744; found: 473.0735 [M+Na]+.
Compound 2f: 1H NMR (300 MHz, DMSO-d6): d 1.22–1.25 (m, 2H), 1.37 (s, 9H),
C. Madhu et al. / Tetrahedron Letters 55 (2014) 6831–6835 68351.38–1.41 (m, 2H), 1.50–1.53 (m, 2H), 2.85 (t, 2H, J = 4.8 Hz), 3.72 (t, 1H,
J = 4.2 Hz), 5.18 (s, 2H), 6.88 (br, 1H), 7.10 (br, 1H), 7.12–7.16 (m, 5H), 9.56 (br
s, 1H), 9.92 (br s, 1H); 13C NMR (75 MHz, CDCl3): 21.9, 27.9, 31.2, 33.5, 40.8,
50.3, 66.1, 78.5, 127.2, 127.6, 129.8, 140.9, 151.9, 153.3, 197.1; 77Se NMR
(75 MHz, CDCl3): d 517.1; HRMS (m/z) calcd for: C19H29N3O4SeNa 466.1221;
found: 466.0982 [M+Na]+.
Compound 2i: 1H NMR (300 MHz, DMSO-d6): d 2.72 (d, 2H, J = 6.6 Hz), 3.61 (s,
2H), 3.81 (t, 1H, J = 3.8 Hz), 5.37 (s, 2H), 7.05 (br, 1H), 7.12–7.19 (m, 10H), 9.88
(br s, 1H), 10.07 (br s, 1H); 13C NMR (75 MHz, DMSO-d6): 35.5, 39.5, 53.2, 65.9,
127.2, 127.6, 127.9, 128.2, 128.6, 128.8, 137.2, 141.3, 152.2, 196.7; 77Se NMR
(75 MHz, DMSO-d6): d 497.8; HRMS (m/z) calcd for: C18H20N2O2SSeNa
431.0308; found: 431.0314 [M+Na]+.
Compound 4a: 1H NMR (300 MHz, CDCl3): d 0.95 (d, 6H, J = 6.2 Hz), 1.17 (d, 6H,
J = 6.4 Hz), 1.38 (s, 9H), 1.52–1.57 (m, 2H), 1.71–1.74 (m, 1H), 2.33–2.37 (m,
1H), 3.25 (d, 1H, J = 6.8 Hz), 4.21 (t, 1H, J = 5.2 Hz), 5.15 (s, 1H), 5.31 (s, 2H),
5.75 (br, 1H), 6.62 (br, 1H), 7.15–7.19 (m, 5H); 13C NMR (75 MHz, CDCl3): 17.8,
21.2, 24.5, 29.3, 32.7, 41.4, 49.8, 56.9, 65.7, 81.1, 114.5, 127.1, 127.6, 128.5,
141.4, 149.8, 155.7, 156.5, 174.5; 77Se NMR (75 MHz, CDCl3): d 656.3; HRMS
(m/z) calcd for: C25H37N3O4SeNa 546.1847; found: 546.1884 [M+Na]+.Compound 4b: 1H NMR (300 MHz, CDCl3): d 1.10 (d, 6H, J = 7.4 Hz), 1.35 (s,
9H), 1.67–1.93 (m, 3H), 2.63 (d, 2H, J = 5.6 Hz), 3.41 (t, 1H, J = 4.8 Hz), 4.16 (t,
1H, J = 5.2 Hz), 4.41 (t, 1H, J = 7.0 Hz), 4.68 (d, 2H, J = 7.0 Hz), 5.17 (s, 1H), 6.15
(br, 1H), 6.92 (br, 1H), 7.13–7.78 (m, 13H); 13C NMR (75 MHz, CDCl3): 23.5,
24.7, 29.1, 35.2, 38.7 41.1, 47.4, 55.2, 67.7, 80.4, 115.9, 126.1, 126.6, 127.7,
128.1, 128.5, 128.7, 129.2, 138.8, 141.5, 143.2, 151.5, 156.3, 157.2, 175.4; 77Se
NMR (75 MHz, CDCl3): d 681.7; HRMS (m/z) calcd for: C36H41N3O4SeNa
682.2160; found: 682.2195 [M+Na]+.
Compound 4e: 1H NMR (300 MHz, CDCl3): d 1.34 (d, 3H, J = 7.2 Hz), 2.51 (d, 2H,
J = 6.8 Hz), 3.85 (t, 1H, J = 4.6 Hz),), 4.32 (t, 1H, J = 6.2 Hz), 4.42–4.47 (m, 1H),
4.78 (d, 2H, J = 6.2 Hz), 5.12 (s, 1H), 5.28 (s, 2H), 6.31 (br, 1H), 6.92 (br, 1H),
7.15–7.71 (m, 18H); 13C NMR (75 MHz, CDCl3): 17.6, 35.4, 45.1, 47.3, 54.0,
65.7, 68.2, 110.9, 126.4, 126.8, 127.3, 127.6, 127.8, 128.3, 128.5, 128.7, 128.9,
129.2, 139.2, 140.8, 141.5, 143.2, 152.1, 156.2, 157.5, 171.8; 77Se NMR
(75 MHz, CDCl3): d 681.1; HRMS (m/z) calcd for: C36H33N3O4SeNa 674.1534;
found: 674.1527 [M+Na]+.
